Literature DB >> 9152741

Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity.

E Näslund1, P Grybäck, P M Hellström, H Jacobsson, J J Holst, E Theodorsson, L Backman.   

Abstract

OBJECTIVE: Some studies have shown a more rapid gastric emptying in obese subjects. Six to twelve months after jejunoileal bypass (JIB) neurotensin (NT) and enteroglucagon have been shown to be elevated after food intake. These hormones, together with peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) have been implicated in the reduction of upper gastrointestinal motility seen after infusion of nutrients into the ileum. AIM: To study if the postprandial gut hormone pattern and gastric emptying is altered 20 y after JIB.
SUBJECTS: Seven subjects operated with JIB a mean (s.d.) 20 +/- 3 y ago, with a BMI of 44 +/- 4 kg/m2 at the time of surgery and 31 +/- 4 at present. For comparison seven sex-matched non-operated obese controls (BMI 43 +/- 3) were studied.
METHODS: Serial blood samples were obtained every 10 min after intake of a 280 kcal meal. Radioimmunoassays for motilin, cholecystokinin (CCK), NT, PYY and GLP-1 were performed. Gastric emptying of a solid meal was studied using a radioactively labelled omelette (of 310 kcal) for 120 min).
RESULTS: After JIB postprandial motilin, CCK, NT, PYY and GLP-1 were elevated compared to non-operated obese subjects. Similarly, basal levels of CCK, motilin, GLP-1 and PYY were elevated in the operated group. No difference was observed in the rate of gastric emptying between the two groups.
CONCLUSION: Both fasting and postprandial gut hormone levels are elevated 20 y after JIB. The impact of long-term rapid stimulation of the ileum and subsequent raised gut hormone levels on gastric emptying is not clear.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152741     DOI: 10.1038/sj.ijo.0800418

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  53 in total

Review 1.  Role of gastrointestinal hormones in feeding behavior and obesity treatment.

Authors:  Timothy Sean Kairupan; Haruka Amitani; Kai-Chun Cheng; Joshua Runtuwene; Akihiro Asakawa; Akio Inui
Journal:  J Gastroenterol       Date:  2015-09-07       Impact factor: 7.527

Review 2.  Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery.

Authors:  David E Cummings; Joost Overduin; Karen E Foster-Schubert; Molly J Carlson
Journal:  Surg Obes Relat Dis       Date:  2007 Mar-Apr       Impact factor: 4.734

3.  Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.

Authors:  Cecilia Ratner; Zhenyan He; Kaare V Grunddal; Louise J Skov; Bolette Hartmann; Fa Zhang; Annette Feuchtinger; Anette Bjerregaard; Christina Christoffersen; Matthias H Tschöp; Brian Finan; Richard D DiMarchi; Gina M Leinninger; Kevin W Williams; Christoffer Clemmensen; Birgitte Holst
Journal:  Diabetes       Date:  2019-04-01       Impact factor: 9.461

4.  Intragastric injection of botulinum toxin for the treatment of obesity. Where are we?

Authors:  Diego Garcia-Compean; Hector Maldonado Garza
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

Review 5.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

6.  Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery.

Authors:  Mousumi Bose; Julio Teixeira; Blanca Olivan; Baani Bawa; Sara Arias; Sriram Machineni; F Xavier Pi-Sunyer; Philipp E Scherer; Blandine Laferrère
Journal:  J Diabetes       Date:  2010-03       Impact factor: 4.006

7.  Relation of fasting plasma peptide YY to glucose metabolism and cardiovascular risk factors after restrictive bariatric surgery.

Authors:  Ursula Hanusch-Enserer; Mohammed A Ghatei; Edmund Cauza; Steven R Bloom; Rudolf Prager; Michael Roden
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

8.  Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats.

Authors:  M B Mumphrey; L M Patterson; H Zheng; H-R Berthoud
Journal:  Neurogastroenterol Motil       Date:  2012-10-24       Impact factor: 3.598

9.  Endobarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism.

Authors:  Nuria Vilarrasa; Amador García Ruiz de Gordejuela; Anna Casajoana; Xevi Duran; Silvia Toro; Eduard Espinet; Manoel Galvao; Joan Vendrell; Rafael López-Urdiales; Manuel Pérez; Jordi Pujol
Journal:  Obes Surg       Date:  2017-03       Impact factor: 4.129

10.  Hormonal regulators of appetite.

Authors:  Juliana Austin; Daniel Marks
Journal:  Int J Pediatr Endocrinol       Date:  2008-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.